Fb2Gratis.com

Gastroenterological Endoscopy. Группа авторов
Чтение книги онлайн.

Читать онлайн книгу Gastroenterological Endoscopy - Группа авторов страница 73

Информация о книге:

Название: Gastroenterological Endoscopy

Автор: Группа авторов

Издательство: Ingram

Жанр: Медицина

Серия:

isbn: 9783131470133

isbn:

СКАЧАТЬ Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2, Suppl):e326S–e350S

[3] Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008; 168(1):63–69

[4] Fujimoto K, Fujishiro M, Kato M, et al; Japan Gastroenterological Endoscopy Society. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014; 26(1):1–14

[5] Abraham NS, Castillo DL. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol. 2013; 29(6):676–683

[6] Tang RS, Chan FK. Prevention of gastrointestinal events in patients on antithrombotic therapy in the peri-endoscopy period: review of new evidence and recommendations from recent guidelines. Dig Endosc. 2015; 27(5):562–571

[7] Anderson MA, Ben-Menachem T, Gan SI, et al; ASGE Standards of Practice Committee. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009; 70(6):1060–1070

[8] Boustière C, Veitch A, Vanbiervliet G, et al; European Society of Gastrointestinal Endoscopy. Endoscopy and antiplatelet agents. Endoscopy. 2011; 43(5):445–461

[9] Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985; 72(6):1177–1184

[10] Di Minno A, Spadarella G, Prisco D. et al. Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: clinical translation and areas of research. Blood Rev. 2015; 29(5):335–343

[11] Acosta RD, Abraham NS, Chandrasekhara V, et al; ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016; 83(1):3–16

[12] Vanden Daelen S, Peetermans M, Vanassche T. et al. Monitoring and reversal strategies for new oral anticoagulants. Expert Rev Cardiovasc Ther. 2015; 13(1):95–103

[13] Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014; 64(11):1128–1139

[14] Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 2016; 48(4):385–402

[15] Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006; 27(22):2667–2674

[16] Siegal D, Yudin J, Kaatz S. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012; 126(13):1630–1639

[17] Hui AJ, Wong RM, Ching JY. et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004; 59(1):44–48

[18] Kim HG, Friedland S. Safe and effective colon polypectomy in patients receiving uninterrupted anticoagulation: can we do it? Gastrointest Endosc. 2014; 79(3):424–426

[19] Nishimura RA, Otto CM, Bonow RO, et al; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(23):e521–e643

[20] Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012; 126(20):2428–2432

[21] Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion. 2012; 52(Suppl 1):45S–55S

[22] Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol. 2014; 12(2):187–195

[23] Holbrook A, Schulman S, Witt DM, et al; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2, Suppl):e152S–e184S

[24] Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013; 59(2):353–362

[25] Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87(Suppl 1):S141–S145

[26] Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis. 2013; 35(3):391–398